ESMO 2018 | Is CAR T-cell therapy for solid malignancies?
Michel Sadelain
CAR T-cell therapy has good prospects for moving into the field of solid tumors, suggests Michel Sadelain, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. With adjustments, particularly for the tumor microenvironments, Dr Sadelain believes it will be possible to use CAR-T technology in the solid setting.
Similar topics
Related videos

Accelerate, Coordinate, Evaluate (ACE) cancer care: the CRUK programme streamlining the care pathway
Sara Hiom

MR Linac: benefits, usage & research collaborations
Fiona McDonald

Pioneering CAR-Macrophage therapies for solid tumours
Saar Gill

How to manage elderly patients on immunotherapy
Matti Aapro

Educating for excellence: educating patients and advocates
Jan Geissler